Silver Book Fact

A prostate cancer vaccine, sipleucel-T immunotherapy, in men with metastatic castration-resistant prostate
cancer, reduced the risk of death by 22 percent compared to placebo, and represented a 4.2 month improvement in median survival.

Kantoff P, Higano C, Shore N, Berger E, et al. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. NEJM. 2010; 363: 411-22. http://www.nejm.org/doi/full/10.1056/NEJMoa1001294

Reference

Title
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Publication
NEJM
Publication Date
2010
Authors
Kantoff P, Higano C, Shore N, Berger E, et al.
Pages
411-22
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • There are nearly 14.5 million people in the U.S. living with a history of cancer.  
  • Cancer Survivors in the United States  
  • Because of advances in treatment, the 5-year survival rate for people with actue lymphocytic leukemia has increased from 38% in 1974-1976 to 65% in 1995-2001.  
  • When detected early, the 5-year survival rate for colorectal cancer is 90%; however, only 39% of colorectal cancers are diagnosed early, mainly because of low rates of screening.  
  • From 1975 to 1996, new cancer drugs increased life expectancy of cancer patients by about one year, at an estimated cost of $3,000—well below the estimated value of a statistical…